Key result
Pharmacological challenge with adrenaline and procainamide infusions diagnosed a primary electrical disease in 67% of patients with unexplained cardiac arrest, including CPVT (56%) and Brugada (11%).
Why the study?
Does pharmacological challenge with adrenaline and procainamide infusions improve the diagnosis of primary electrical disease in patients with unexplained cardiac arrest and their family members?
Observational (n=18)
Does pharmacological challenge with adrenaline and procainamide infusions improve the diagnosis of primary electrical disease in patients with unexplained cardiac arrest and their family members?
Provocative testing with adrenaline and procainamide is highly effective in unmasking latent primary electrical diseases like CPVT and Brugada syndrome in patients with unexplained cardiac arrest and their relatives.
Answers are grounded in this paper and cite their sources.
May support pharmacological challenge in unexplained cardiac arrest; hypothesis-generating and requires larger prospective validation.
BACKGROUND: Cardiac arrest with preserved left ventricular function may be caused by uncommon genetic conditions. Although these may be evident on the ECG, long-term monitoring or provocative testing is often necessary to unmask latent primary electrical disease. METHODS AND RESULTS: Patients with unexplained cardiac arrest and no evident cardiac disease (normal left ventricular function, coronary arteries, and resting corrected QT) underwent pharmacological challenge with adrenaline and procainamide infusions to unmask subclinical primary electrical disease. Family members underwent noninvasive screening and directed provocative testing on the basis of findings in the proband. Eighteen patients (mean+/-SD age, 41+/-17 years; 11 female) with unexplained cardiac arrest were assessed. The final diagnosis was catecholaminergic ventricular tachycardia (CPVT) in 10 patients (56%), Brugada syndrome in 2 patients (11%), and unexplained (idiopathic ventricular fibrillation) in 6 patients (33%). Of 55 family members (mean+/-SD age, 27+/-17 years; 33 female), 9 additional affected family members were detected from 2 families, with a single Brugada syndrome patient and 8 CPVT patients. CONCLUSIONS: Provocative testing with adrenaline and procainamide infusions is useful in unmasking the etiology of apparent unexplained cardiac arrest. This approach helps to diagnose primary electrical disease, such as CPVT and Brugada syndrome, and provides the opportunity for therapeutic intervention in identified, asymptomatic family members who harbor the same disease.
No takes yet. Share an insight, caveat, or question.
Krahn et al. (2005) conducted an observational in Unexplained cardiac arrest (n=18). Pharmacological challenge with adrenaline and procainamide infusions was evaluated on Final diagnosis of subclinical primary electrical disease. Pharmacological challenge with adrenaline and procainamide infusions diagnosed a primary electrical disease in 67% of patients with unexplained cardiac arrest, including CPVT (56%) and Brugada (11%).
Synapse has enriched 10 related papers. Consider them for comparative context: